Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
60 hedge funds and large institutions have $11.1M invested in Anthera Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 16 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
2% more capital invested
Capital invested by funds: $10.8M → $11.1M (+$258K)
17% less funds holding
Funds holding: 72 → 60 (-12)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
88% less call options, than puts
Call options by funds: $12K | Put options by funds: $102K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.72M |
| 2 |
BlackRock
New York
|
+$1.71M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$985K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$546K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$542K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.19M |
| 2 |
A
Abingworth
London,
United Kingdom
|
-$1.17M |
| 3 |
Millennium Management
New York
|
-$165K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$137K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$133K |
ANTH Hedge Fund Activity: Q1 2017 in Review
60 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q1 2017, worth a combined $11.1M — up 2.4% from $10.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ANTH and 9 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 20 added.
The largest buyer was BVF Inc, adding an estimated $4.72M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.19M sold.
- 60 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q1 2017, down from 72 in Q4 2016.
- Funds reported $11.1M of Anthera Pharmaceuticals, Inc. stock for Q1 2017, up 2.4% quarter-over-quarter.
- 9 funds opened new Anthera Pharmaceuticals, Inc. positions in Q1 2017 and 16 closed out, a net change of -7 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q1 2017 was BVF Inc, an estimated $4.72M added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q1 2017 was Fidelity Investments, an estimated $1.19M sold.
Based on aggregated 13F filings for Q1 2017.